vida: extract claims from 2026-04-22-npr-glp1-coverage-decline-insurance-slipping-2026

- Source: inbox/queue/2026-04-22-npr-glp1-coverage-decline-insurance-slipping-2026.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap.md

@@ -39,3 +39,10 @@ Scope resolution: the 3.6M → 2.8M covered lives decline (22% reduction) applie
 **Source:** National Law Review, FDA April 1 2026 clarification
 
 The FDA's April 2026 clarification targeted combination formulations (semaglutide + vitamin B12) that compounders used to escape the 'essentially a copy' standard, signaling regulatory skepticism. The 503A safe harbor requires individualized clinical justification from prescribers demonstrating 'significant difference' for each patient, with boilerplate clinical rationale deemed insufficient. This creates additional administrative burden that further constrains the compounding access pathway even within the 4 Rx/month limit.
+
+
+## Supporting Evidence
+
+**Source:** NPR April 22, 2026; KFF Employer Health Benefits Survey 2024-2025
+
+NPR provides second-source confirmation of the 3.6M → 2.8M covered lives decline (22% reduction) between 2024 and 2026. Multiple employers in NPR focus groups reported firms 'will no longer cover GLP-1 agonists for weight loss.' The KFF survey paradox (both 'offers' and 'doesn't offer' percentages increasing from 2024 to 2025) suggests mid-year plan changes are common — employers are actively revising coverage policies in response to cost pressures. The Mercer data (66% say GLP-1 had 'significant' impact on prescription drug spending) confirms the cost pressure mechanism driving the access retreat.

domains/health/glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-23-icer-glp1-affordable-access-2025.md
 scope: structural
 sourcer: ICER
 supports: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medicaid-glp1-coverage-reversing-through-state-budget-pressure"]
-related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift"]
+related: ["glp-1-receptor-agonists-are-the-largest-therapeutic-category-launch-in-pharmaceutical-history-but-their-chronic-use-model-makes-the-net-cost-impact-inflationary-through-2035", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift", "glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap"]
 ---
 
 # GLP-1 obesity coverage creates acute payer fiscal crisis with employer plans experiencing >10x PMPM cost increases in 2023-2024 and major insurers reporting operating losses driven primarily by GLP-1 expenditures
@@ -38,3 +38,10 @@ Evernorth EncircleRx reports ~$200 million saved since 2024 across 9 million enr
 **Source:** DistilINFO April 2026
 
 Blue Cross Blue Shield Michigan reported $350M increase in GLP-1 drug costs in 2023 alone. Blue Cross Blue Shield Massachusetts reported $400M operating loss in 2024 driven largely by GLP-1 spending. These are major regional Blues plans with broad population coverage, confirming the fiscal unsustainability is affecting diverse payer types, not just large employers.
+
+
+## Supporting Evidence
+
+**Source:** Mercer 2026 Survey; NPR April 22, 2026
+
+Mercer 2026 survey confirms the fiscal pressure mechanism: 59% of the biggest employers (5,000+ workers) report GLP-1 costs exceeded expectations, and 66% say GLP-1 had 'significant' impact on prescription drug spending. One employer reported GLP-1 weight-loss spending increasing 50% year over year. This cost acceleration is driving the coverage withdrawal documented in the 3.6M → 2.8M covered lives decline. The fiscal unsustainability is producing behavioral responses: 77% of large employers prioritize managing GLP-1 costs as 'extremely or very important,' indicating cost management has become a top-tier strategic priority.

inbox/archive/health/2026-04-22-npr-glp1-coverage-decline-insurance-slipping-2026.md

@@ -7,10 +7,13 @@ date: 2026-04-22
 domain: health
 secondary_domains: []
 format: thread
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-01
 priority: high
 tags: [GLP-1, obesity, employer-coverage, covered-lives, insurance-access, cost-crisis, Wegovy, Zepbound]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content